I graduated from the University of Georgia and the Medical College of Georgia before pursuing pediatrics residency training at Cincinnati Children's. I trained in pediatric hematology-oncology at the Children's Hospital of Philadelphia where I developed a keen interest in the biology and therapy of pediatric sarcomas. I spent 11 years at the University of Alabama at Birmingham School of Medicine and Children's Hospital of Alabama where I functioned as the principal investigator (PI) for the Children's Oncology Group (COG) Phase 1 and Pilot Consortium and the Sarcoma Alliance for Research through Collaboration (SARC).
I joined the Cancer and Blood Diseases Institute at Cincinnati Children's to direct the Sarcoma and Young Adult Oncology Programs in 2014. I am appointed Professor of Clinical Pediatrics at the University of Cincinnati College of Medicine and function as the Cincinnati Children's Institutional PI for the COG Pediatric Early Phase Clinical Trials Network (PEP-CTN) and SARC, as well as for many industry-sponsored trials.
MD: Medical College of Georgia, Augusta, GA, 1995.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1998.
Fellowship: Pediatric Hematology-Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 2001.
Certification: Pediatric Hematology-Oncology, 2002.
Pediatric and young adult patients with musculoskeletal tumors including rhabdomyosarcoma and other soft-tissue sarcomas; desmoid tumors; Ewing sarcoma; osteosarcoma; pediatric solid tumors; rare tumors including small cell carcinoma of the ovary
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Challenges in the Treatment of Sarcomas of Adolescents and Young Adults. Journal of Adolescent and Young Adult Oncology. 2017; 6:406-413.
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatric Blood and Cancer. 2025; e31692.
Abstract 3155: High-throughput drug repositioning identifies dinaciclib as a potent osteosarcoma inhibitor. Cancer Research. 2025; 85:3155.
23P Pre-diagnostic imaging reveals rapid emergence and progression of small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Implications for monitoring carriers of SMARCA4 germline pathogenic variants (GPVs). ESMO Open. 2025; 10:104332.
"From Drowning to Treading Water ": Adolescents and Young Adults Living with Incurable and Indolent Metastatic Soft Tissue Sarcoma for More than Two Years. Cancers. 2025; 17:442.
Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Genetics in Medicine. 2025; 27:101287.
Body Image Concerns in Adolescent and Young Adult Oncology Patients within Six Months of Upfront Diagnosis. Journal of Adolescent and Young Adult Oncology. 2024; 13:792-798.
Antiresorptive and anti-angiogenic drug therapy in the pediatric population with reference to medication-related osteonecrosis of the jaw. International Journal of Oral and Maxillofacial Surgery. 2024; 53:496-502.
Fluorescent-guided surgery and the use of indocyanine green sentinel lymph node mapping in the pediatric and young adult oncology population. Cancer. 2023; 129:3962-3970.
Atypical Presentation of Granulosa Cell Tumor in an Adolescent: A Case Report. Journal of Pediatric and Adolescent Gynecology. 2023; 36:553-555.
3/29/2018
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey